These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3079494)

  • 1. NIH Consensus Development Conference. Management of clinically localized prostate cancer.
    Oncology (Williston Park); 1987 Nov; 1(9):46-9, 54. PubMed ID: 3079494
    [No Abstract]   [Full Text] [Related]  

  • 2. Consensus development summaries. The management of clinically localized prostate cancer. National Institutes of Health.
    Conn Med; 1987 Sep; 51(9):607-10. PubMed ID: 3311616
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
    Hennenfent BR
    Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Improving outcomes for primary and salvage therapy of localized prostate cancer.
    Schellhammer PF
    J Urol; 2003 Nov; 170(5):1841-2. PubMed ID: 14532788
    [No Abstract]   [Full Text] [Related]  

  • 5. Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel.
    NCI Monogr; 1988; (7):3-6. PubMed ID: 3050539
    [No Abstract]   [Full Text] [Related]  

  • 6. Consensus conference. The management of clinically localized prostate cancer.
    JAMA; 1987 Nov; 258(19):2727-30. PubMed ID: 3312666
    [No Abstract]   [Full Text] [Related]  

  • 7. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
    D'Amico AV; Desjardin A; Chung A; Chen MH; Schultz D; Whittington R; Malkowicz SB; Wein A; Tomaszewski JE; Renshaw AA; Loughlin K; Richie JP
    Cancer; 1998 May; 82(10):1887-96. PubMed ID: 9587121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer of the prostate: what treatment for what stage?].
    Vanden Bossche M
    Rev Med Brux; 1999 Sep; 20(4):A206-11. PubMed ID: 10523894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of prostate cancer].
    Auvert J
    Ann Urol (Paris); 1999; 33(4):259-62. PubMed ID: 10510707
    [No Abstract]   [Full Text] [Related]  

  • 12. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    Dahm P; Yeung LL; Chang SS; Cookson MS
    J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health.
    Halperin EC; Fraser RW; Hughes J
    N C Med J; 1988 Feb; 49(2):75-9. PubMed ID: 3278241
    [No Abstract]   [Full Text] [Related]  

  • 14. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservative management of clinically-localized prostate cancer.
    Chodak G
    Can J Oncol; 1994 Nov; 4 Suppl 1():20-1; discussion 22-3. PubMed ID: 8853484
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
    Sandler HM; Eisenberger MA
    J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of stage A1 prostate cancer: the case for treatment.
    Bahnson RR
    Semin Urol; 1993 May; 11(2):54-7. PubMed ID: 7689739
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment strategy of localized prostate cancer].
    Maeda O
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):26-31. PubMed ID: 12557701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of clinically localized prostate cancer.
    Natl Inst Health Consens Dev Conf Consens Statement; 1987 Jun 15-17; 6(10):1-6. PubMed ID: 3317009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.